Diagnostic strategy for patients with hypogammaglobulinemia in rheumatology

Joint Bone Spine

Volumn 78, Issue 3, 2011, Pages 241-245

  Samson, Maxime ^a,b   Audia, Sylvain ^a,b   Lakomy, Daniela ^a,b   Bonnotte, Bernard ^a,b   Tavernier, Christian ^c   Ornetti, Paul ^c,d  

^a DIJON UNIVERSITY HOSPITAL   (France)

^b Chu   (France)

^c HÔPITAL DU BOCAGE   (France)

^d INSERM   (France)

Author keywords

Chronic inflammatory rheumatism; Diagnosis; Etiologies; Hypogammaglobulinemia; Primary immunodeficiency

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; CAPTOPRIL; CARBAMAZEPINE; CHLORPROMAZINE; CLONAZEPAM; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETIRACETAM; GOLD SALT; IMATINIB; LEVOTHYROXINE; PENICILLAMINE; PHENOBARBITAL; PHENYTOIN; RITUXIMAB; SALAZOSULFAPYRIDINE; THYROXINE; VALPROIC ACID;

B LYMPHOCYTE; BLOOD DISEASE; COMMON VARIABLE IMMUNODEFICIENCY; CONSULTATION; DIAGNOSTIC PROCEDURE; ELECTROPHORESIS; HAEMOPHILUS INFLUENZAE; HEPATOMEGALY; HUMAN; IMMUNE DEFICIENCY; IMMUNE DYSREGULATION; IMMUNOGLOBULIN DEFICIENCY; LYMPHADENOPATHY; PATHOGENICITY; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SHORT SURVEY; SPLENOMEGALY; STREPTOCOCCUS PNEUMONIA; SUBSTITUTION THERAPY;

ADULT; AGAMMAGLOBULINEMIA; DECISION TREES; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOGLOBULINS; IMMUNOLOGIC DEFICIENCY SYNDROMES; REFERRAL AND CONSULTATION; RHEUMATIC DISEASES; RHEUMATOLOGY; YOUNG ADULT;

EID: 79955532370     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2010.09.016     Document Type: Short Survey

References (50)

1. Sibilia J., Gottenberg J.E., Mariette X. Rituximab: a new therapeutic alternative in rheumatoid arthritis. Joint Bone Spine 2008, 75:526-532.
2. Chames P., Van Regenmortel M., Weiss E., et al. Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol 2009, 157:220-233.
3. Revillard JP. Immunologie. 4e ed. Bruxelles, De Boeck Université; 2001.
4. Cabanillas F., Liboy I., Pavia O., et al. High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication. Ann Oncol 2006, 17:1424-1427.
5. Cunningham-Rundles C., Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol 1999, 92:34-48.
6. Hargreaves R.M., Lea J.R., Griffiths H., et al. Immunological factors and risk of infection in plateau phase myeloma. J Clin Pathol 1995, 48:260-266.
7. Michel M., Chanet V., Galicier L., et al. Autoimmune thrombocytopenic purpura and common variable immunodeficiency: analysis of 21 cases and review of the literature. Medicine (Baltimore) 2004, 83:254-263.
8. Sordet C., Cantagrel A., Schaeverbeke T., et al. Bone and joint disease associated with primary immune deficiencies. Joint Bone Spine 2005, 72:503-514.
9. Kato Z., Watanabe M., Kondo N. IgG2, IgG4 and IgA deficiency possibly associated with carbamazepine treatment. Eur J Pediatr 2003, 162:209-211.
10. Go T. Carbamazepine-induced IgG1 and IgG2 deficiency associated with B cell maturation defect. Seizure 2004, 13:187-190.
11. Moreno-Ancillo A., Cosmes Martin P.M., Dominguez-Noche C., et al. Carbamazepine induced transient monoclonal gammopathy and immunodeficiency. Allergol Immunopathol (Madr) 2004, 32:86-88.
12. Yabuki S., Nakaya K. Immunoglobulin abnormalities in epileptic patients treated with diphenylhydantoin. Folia Psychiatr Neurol Jpn 1976, 30:93-109.
13. Britigan B.E. Diphenylhydantoin-induced hypogammaglobulinemia in a patient infected with human immunodeficiency virus. Am J Med 1991, 90:524-527.
14. Ishizaka A., Nakanishi M., Kasahara E., et al. Phenytoin-induced IgG2 and IgG4 deficiencies in a patient with epilepsy. Acta Paediatr 1992, 81:646-648.
15. Braconier J.H. Reversible total IgA deficiency associated with phenytoin treatment. Scand J Infect Dis 1999, 31:515-516.
16. Pereira L.F., Sanchez J.F. Reversible panhypogammaglobulinemia associated with phenytoin treatment. Scand J Infect Dis 2002, 34:785-787.
17. So A.K., Peskett S.A., Webster A.D. Hypogammaglobulinaemia associated with gold therapy. Ann Rheum Dis 1984, 43:581-582.
18. Burns H.J., Klimiuk P.S., Hilton R.C., et al. Gold-induced hypogammaglobulinaemia. Br J Rheumatol 1987, 26:53-55.
19. Delamere J.P., Farr M., Grindulis K.A. Sulphasalazine induced selective IgA deficiency in rheumatoid arthritis. Br Med J (Clin Res Ed) 1983, 286:1547-1548.
20. Farr M., Tunn E., Bacon P.A., et al. Hypogammaglobulinaemia and thrombocytopenia associated with sulphasalazine therapy in rheumatoid arthritis. Ann Rheum Dis 1985, 44:723-724.
21. Farr M., Kitas G.D., Tunn E.J., et al. Immunodeficiencies associated with sulphasalazine therapy in inflammatory arthritis. Br J Rheumatol 1991, 30:413-417.
22. Cissoko H., Jonville-Bera A.P., Lenain H., et al. Agranulocytosis and transitory immune deficiency after fetal exposure to azathioprine and mesalazine. Arch Pediatr 1999, 6:1136-1137.
23. Biasi D., Carletto A., Caramaschi P., et al. Efficacy of methotrexate in the treatment of ankylosing spondylitis: a three-year open study. Clin Rheumatol 2000, 19:114-117.
24. McLaughlin P., Grillo-Lopez A.J., Link B.K., et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998, 16:2825-2833.
25. Lim S.H., Zhang Y., Wang Z., et al. Maintenance rituximab after autologous stem cell transplant for high-risk B-cell lymphoma induces prolonged and severe hypogammaglobulinemia. Bone Marrow Transplant 2005, 35:207-208.
26. Kosmidis S., Baka M., Bouhoutsou D., et al. Longitudinal assessment of immunological status and rate of immune recovery following treatment in children with ALL. Pediatr Blood Cancer 2008, 50:528-532.
27. Keystone E., Fleischmann R., Emery P., et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 2007, 56:3896-3908.
28. Genovese M.C., Breedveld F.C., Emery P., et al. Safety of biological therapies following rituximab treatment in rheumatoid arthritis patients. Ann Rheum Dis 2009, 68:1894-1897.
29. van Vollenhoven R.F., Emery P., Bingham C.O., et al. Long-term safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol 2010, 37:558-567.
30. Lee R.J., Fay A.C. Hypogammaglobulinaemia associated with long term, low dose steroid therapy. Postgrad Med J 1985, 61:523-524.
31. Klaustermeyer W.B., Gianos M.E., Kurohara M.L., et al. IgG subclass deficiency associated with corticosteroids in obstructive lung disease. Chest 1992, 102:1137-1142.
32. Kawano T., Matsuse H., Obase Y., et al. Hypogammaglobulinemia in steroid-dependent asthmatics correlates with the daily dose of oral prednisolone. Int Arch Allergy Immunol 2002, 128:240-243.
33. Levy A.L., Waldmann T.A. The effect of hydrocortisone on immunoglobulin metabolism. J Clin Invest 1970, 49:1679-1684.
34. Hamilos D.L., Young R.M., Peter J.B., et al. Hypogammaglobulinemia in asthmatic patients. Ann Allergy 1992, 68:472-481.
35. Bjorneboe M., Fischel E.E., Stoerk H.C. The effect of cortisone and adrenocorticotrophic hormone on the concentration of circulating antibody. J Exp Med 1951, 93:37-48.
36. Nishio M., Endo T., Fujimoto K., et al. Persistent panhypogammaglobulinemia with selected loss of memory B cells and impaired isotype expression after rituximab therapy for post-transplant EBV-associated autoimmune hemolytic anemia. Eur J Haematol 2005, 75:527-529.
37. Walker A.R., Kleiner A., Rich L., et al. Profound hypogammaglobulinemia 7 years after treatment for indolent lymphoma. Cancer Invest 2008, 26:431-433.
38. Tsai H.T., Caporaso N.E., Kyle R.A., et al. Evidence of serum immunoglobulin abnormalities up to 9.8 years before diagnosis of chronic lymphocytic leukemia: a prospective study. Blood 2009, 114:4928-4932.
39. Lassoued K., Clauvel J.P., Similowski T., et al. Pulmonary infections associated with systemic capillary leak syndrome attacks in a patient with hypogammaglobulinemia. Intensive Care Med 1998, 24:981-983.
40. Chapel H., Lucas M., Lee M., et al. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood 2008, 112:277-286.
41. Geha R.S., Notarangelo L.D., Casanova J.L., et al. Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee. J Allergy Clin Immunol 2007, 120:776-794.
42. Gathmann B., Grimbacher B., Beaute J., et al. The European internet-based patient and research database for primary immunodeficiencies: results 2006-2008. Clin Exp Immunol 2009, 157(Suppl. 1):3-11.
43. Park M.A., Li J.T., Hagan J.B., et al. Common variable immunodeficiency: a new look at an old disease. Lancet 2008, 372:489-502.
44. Cunningham-Rundles C. Hematologic complications of primary immune deficiencies. Blood Rev 2002, 16:61-64.
45. Yong P.F., Chee R., Grimbacher B. Hypogammaglobulinaemia. Immunol Allergy Clin North Am 2008, 28:691-713. [vii].
46. Castigli E., Wilson S.A., Garibyan L., et al. TACI is mutant in common variable immunodeficiency and IgA deficiency. Nat Genet 2005, 37:829-834.
47. Salzer U., Chapel H.M., Webster A.D., et al. Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. Nat Genet 2005, 37:820-828.
48. Good R.A., Maclean L.D., Varco R.L., et al. Thymic tumor and acquired agammaglobulinemia: a clinical and experimental study of the immune response. Surgery 1956, 40:1010-1017.
49. Tarr P.E., Sneller M.C., Mechanic L.J., et al. Infections in patients with immunodeficiency with thymoma (Good syndrome). Report of 5 cases and review of the literature. Medicine (Baltimore) 2001, 80:123-133.
50. Fieschi C., Malphettes M., Galicier L., et al. Adult-onset primary hypogammaglobulinemia. Presse Med 2006, 35:887-894.